



THOMSON REUTERS RESEARCH BY DISEASE CATEGORY

A Select List of Recently Published Work by Thomson Reuters Researchers

Since 1988, researchers at Thomson Reuters have conducted studies of disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. Since 2000, these studies have resulted in over 300 peer-reviewed articles published in leading journals, which have made a substantial contribution to the body of literature used to formulate policy decisions and improve healthcare for Americans.

Authors in bold typeface are (or were at the time the work was written) Thomson Reuters staff.

Cardiovascular

Amin AN, **Lin J**, **Lenhart G**, **Schulman KL**. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis* 2009; 102(2): 321–6.

Burleigh E, Wang C, **Foster D**, **Heller S**, **Dunn D**, **Safavi K**, **Griffin B**, **Smith J**. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. *American Journal of Health System-Pharmacy* 2006; 63(20 Suppl 6): S23–9.

Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. *Annals of Epidemiology* 2006; 16(1): 63–70.

Curkendall SM, Lanes S, de Luise C, Stang MR, Jones JK, She D, Goehring E Jr. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. *European Journal of Epidemiology* 2006; 21(11): 803–13.

Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. *Journal of Clinical Psychiatry* 2004; 65(5): 715–20.

Foley KA, Denke MA, Kamal-Bahl S, Simpson Jr R, Berra K, Sajjan S, Alexander CM. The impact of physician attitudes and beliefs on treatment decisions: Lipid therapy in high-risk patients. *Medical Care* 2006; 44(5): 421–428.



- Huse DM, Song X, Ozminkowski RJ**, Maguire J, Williams SA, Borok GM, McDonough K. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. *Clinical Therapeutics* 2006; 28(9): 1425–42.
- Mark T**, Axelsen K, **Mucha L, Sadkova Y**. Racial differences in switching, augmentation and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. *The American Journal of Managed Care* 2007; 13 Suppl 3: S72–9.
- Mark TL, Gibson TB**, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Managed Care* 2009; 15(2): 123–31.
- Martin M**, Blaisdell-Gross B, Fortin EW, Maruish ME, Manocchia M, Sun X, Walker DR, Apple JL, Ware JE. Health-related quality of life of heart failure and coronary artery disease patients improved during participation in disease management programs: A longitudinal observational study. *Disease Management* 2007; 10(3): 164–78.
- Nallamotheu BK, **Young J**, Gurm HS, **Pickens G, Safavi K**. Recent trends in hospital utilization for acute myocardial infarction and coronary revascularization in the United States. *American Journal of Cardiology* 2007; 99(6): 749–53.
- vanVonno CJ, **Ozminkowski RJ**, Smith MW, Thomas EG, Kelley D, **Goetzel R**, Berg GD, Jain SK, Walker DR. What can a pilot congestive heart failure disease management program tell us about likely return on investment? A case study from a program offered to federal employees. *Disease Management* 2005; 8(6): 346–360.
- Wang C, Kereiakes DJ, Bae JP, McCollam P, He J, **Griffin B**. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. *The Journal of Invasive Cardiology* 2007; 19(10): 431–6.
- Wasserman J**, Whitmer RW, Bazzarre TL, **Kennedy ST, Merrick N, Goetzel RZ, Dunn RL, Ozminkowski RJ**, HERO Research Committee. Gender-specific effects of modifiable health risk factors on coronary heart disease and related expenditures. *Journal of Occupational and Environmental Medicine* 2000; 42(11): 1060–1069.
- Xuan J, Duong P, **Russo P**, Lacey MJ, Fu Q, Wong B. The economic burden of congestive heart failure in a managed care population. *The American Journal of Managed Care* 2000; 6(6): 693–700.

Diabetes

- Cohen FJ, Neslusan CA, **Conklin JE, Song X**. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. *Diabetes Care* 2003; 26(6): 1847–1851.
- Curkendall SM**, Natoli JL, Alexander CM, Nathanson BH, Haidar T, Dubois RW. Inpatient diabetic hypoglycemia: Economic and clinical impact. *Endocrine Practice* 2009; May 6; [Epub ahead of print].



- Orzeck EA, **Shi N**, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clinical Therapeutics* 2007; 29(10): 2246–55.
- Ozminkowski R, Wang S, Marder WD, Azzolini J**. Short-run associations between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. *Value in Health* 2000; 3(s1): 29–38.
- Rhoads GG, **Orsini LS, Crown W, Wang S**, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. *Journal of Occupational and Environmental Medicine* 2005; 47(5): 447–452.
- Wasserman J**, Boyce-Smith G, Hopkins DS, **Schabert V**, Davidson MB, **Ozminkowski RJ**, Albright A, **Kennedy S**. A comparison of diabetes patients' self-reported health status with hemoglobin A1c test results in 11 California health plans. *Managed Care* 2001; 10(3): 58–70.

Drug Spending

- Botteman MF, **Ozminkowski RJ, Wang S**, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: A decision analytical model. *CNS Drugs* 2007; 21(4): 319–334.
- Chawla AJ**, Hatzmann MH, **Long SR**. Developing performance measures for prescription drug management. *Health Care Financing Review* 2001; 22(3): 71–84.
- Dubois RW, **Chawla AJ, Neslusan CA, Smith MW**, Wade S. Explaining drug spending trends: Does perception match reality? *Health Affairs* 2000; 19(2): 231–239.
- Gibson TB, Mark TL**, Axelsen K, **Baser O**, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. *American Journal of Managed Care* 2006; 12(12 Spec No): SP11–9.
- Gibson TB, Mark TL**, McGuigan KA, Axelsen K, **Wang S**. The effects of prescription drug copayments on statin adherence. *American Journal of Managed Care* 2006; 12(9): 509–17.
- Gibson TB**, McLaughlin CG, Smith DG. Cost-sharing for prescription drugs. *The Journal of the American Medical Association* 2001; 285(18): 2328–9.
- Gibson TB**, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures. *Inquiry* 2005; 42: 293–310.
- Gibson TB, Ozminkowski RJ, Goetzel RZ**. The effects of prescription drug cost sharing: A review of the evidence. *The American Journal of Managed Care* 2005; 11: 730–740.
- Goetzel RZ, Ozminkowski RJ, Del Rosso G, Schutt DC**. Are drugs a cost or an investment? *Business & Health* 2000; June: 39–45.
- Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC**. Pharmaceuticals—Cost or investment? An employer's perspective. *Journal of Occupational and Environmental Medicine* 2000; 42(4): 338–351.



- Goetzel RZ, Ozminkowski RJ, Schutt DC.** The value of pharmaceuticals—Some direction for employers. *Employee Benefits Journal* 2002; 27(3): 31–35.
- Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G.** Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. *Clinical Drug Investigation* 2007; 27(2): 85–93.
- Mark TL, Ozminkowski RJ.** What will be the impact of the medicare doughnut hole? *Drug Benefit Trends* 2005; June: 254–260.
- Mucha L, Masia NA, Axelsen KJ.** Per-patient-per-month drug costs in Medicare Part D protected classes. *Pharmacoeconomics* 2006; 24 Suppl 3: 79–84.

Allergies and Asthma

.....

- Brixner DI, Lenhart G, Young DC, Samuelson WM.** The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. *Current Medical Research and Opinion* 2007; 23(11): 2887–95.
- Crown WH, Berndt ER, Baser O, Finkelstein SN, Witt WP, Maguire J, Haver KE.** Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Frontiers in Health Policy Research* 2004; 7: 95–127.
- Crown WH, Olufade A, Smith MW, Nathan R.** Seasonal versus perennial allergic rhinitis: Drug and medical resource utilization patterns. *Value in Health* 2003; 6(4): 448–456.
- Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC.** The cost of productivity losses associated with allergic rhinitis. *The American Journal of Managed Care* 2000; 6(3): 373–378.
- Crystal-Peters J, Neslusan C, Crown WH, Torres A.** Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma related hospitalizations and emergency room visits. *The Journal of Allergy and Clinical Immunology* 2002; 109(1): 57–62.
- Crystal-Peters J, Neslusan CA, Smith MW, Togias A.** Health care costs of allergic rhinitis-associated conditions vary with allergy season. *Annals of Allergy, Asthma & Immunology* 2002; 89(5): 457–462.
- Merrick NJ, Houchens R, Tillisch S, Berlow B, Landon C.** Quality of hospital care of children with asthma: Medicaid versus privately insured patients. *Journal of Health Care for the Poor and Underserved* 2001; 12(2): 192–207.
- Orsini L, Limpa-Amara S, Crown WH, Stanford RH, and Kamal K.** Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs. montelukast. *Annals of Allergy, Asthma and Immunology* 2004; 92(5): 523–529.
- Ozminkowski RJ, Wang S, Long SR.** The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. *Disease Management and Health Outcomes* 2007; 15(1): 41–55.



Ozminkowski R, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. *Pharmacoeconomics* 2000; 18(3): 253–264.

Health and Productivity Management

Anderson DR, Whitmer RW, **Goetzel RZ, Ozminkowski RJ**, Dunn RL, Wasserman J, Serxner S; Health Enhancement Research Organization (HERO) Research Committee. The relationship between modifiable health risks and group-level health care expenditures. *American Journal of Health Promotion* 2000; 15(1): 45–52.

Baker KM, Goetzel RZ, Pei X, Weiss AJ, **Bowen J, Tabrizi MJ**, Nelson CF, Metz RD, Pelletier KR, Thompson E. Using a return-on-investment estimation model to evaluate outcomes from an obesity management worksite health promotion program. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 981–990.

Berndt E, **Crown W**, Kallich J, **Long S, Song X**, Lyman GH. The impact of anaemia and its treatment on employee disability and medical costs. *Pharmacoeconomics* 2005; 23(2): 183–192.

Bowen JD, Goetzel RZ, Lenhart G, Ozminkowski RJ, Babamoto KS, Portale JD. Using a personal health care cost calculator to estimate future expenditures based on individual health risks. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 449–55.

Carls G, Li T, Panopolis P, **Wang S, Mell AG, Gibson TB, Goetzel RZ**. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. *Journal of Occupational and Environmental Medicine* 2009; 51(1): 66–79.

Collins JJ, Baase CM, Sharda CE, **Ozminkowski RJ**, Nicholson S, Billotti GM, Turpin RS, Olson M, Berger ML. The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. *Journal of Occupational and Environmental Medicine* 2005; 47(6): 547–557.

Crown W. Productivity measurement in pharmaceutical studies. *Drug Benefit Trends* 2000; 12(2): 5–8.

Della LJ, DeJoy DM, **Goetzel RZ, Ozminkowski RJ**, Wilson MG. Assessing management support for worksite health promotion: psychometric analysis of the leading by example (LBE) instrument. *American Journal of Health Promotion* 2008; 22(5): 359–67.

DeJoy DM, Wilson MG, **Goetzel RZ, Ozminkowski RJ, Wang S**, Baker KM, Bowen HM, Tully KJ. Development of the Environmental Assessment Tool (EAT) to measure organizational physical and social support for worksite obesity prevention programs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 126–137.

Durden ED, Huse D, Ben-Joseph R, **Chu BC**. Economic costs of obesity to self-insured employers. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 991–7.

Goetzel RZ. Better outcomes through health and productivity management. *Managed Care* 2005; 14(10 Suppl): 28–36.



- Goetzel RZ.** Do prevention or treatment services save money? The wrong debate. *Health Affairs* 2009; 28(1): 37–41.
- Goetzel RZ, Baker KM, Short ME, Pei X, Ozminkowski RJ, Wang S, Bowen JD, Roemer EC, Craun BA, Tully KJ, Baase CM, Dejoy DM, Wilson MG.** First-year results of an obesity prevention program at the Dow Chemical Company. *Journal of Occupational and Environmental Medicine* 2009; 51(2): 125–138.
- Goetzel RZ, Carls GS, Wang S, Kelly E, Mauceri E, Columbus D, Cavuoti A.** The relationship between modifiable health risk factors and medical expenditures, absenteeism, short-term disability, and presenteeism among employees at Novartis. *Journal of Occupational and Environmental Medicine* 2009; 51(4): 487–99.
- Goetzel RZ, Guindon AM, Turshen IJ, Ozminkowski RJ.** Health and productivity management: Establishing key performance measures, benchmarks, and best practices. *Journal of Occupational and Environmental Medicine* 2001; 43(1):10–17.
- Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S.** The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. *Journal of Occupational and Environmental Medicine* 2003; 45(1): 5–14.
- Goetzel RZ, Liss-Levinson RC, Goodman N, Kennedy JX.** Development of a community-wide cardiovascular risk reduction assessment tool for small rural employers in upstate New York. *Preventing Chronic Disease* 2009; 6(2): A65.
- Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W.** Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. *Journal of Occupational and Environmental Medicine* 2004; 46(4): 398–412.
- Goetzel RZ, Luisi D, Ozminkowski RJ, Roemer EC, Taher S.** Baseline characteristics of workers at ten New York City employers recruited for a private-public research collaborative. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 190–201.
- Goetzel R, Ozminkowski R.** Integrating to improve productivity. *Journal of Employee Assistance* 2006; 36(4): 25–28.
- Goetzel RZ, Ozminkowski RJ.** What’s holding you back: Why should (or shouldn’t) employers invest in health promotion programs for their workers? *North Carolina Medical Journal* 2006; 67(6): 428–30.
- Goetzel RZ, Ozminkowski RJ.** The health and cost benefits of work site health-promotion programs. *Annual Review of Public Health* 2008; 29: 303–23.
- Goetzel RZ, Ozminkowski RJ, Ascuitto AJ, Chouinard P, Barrett M.** Survey of Koop Award winners: Life-cycle insights. *The Art of Health Promotion* 2001; 5(2).
- Goetzel RZ, Ozminkowski RJ, Baase CM, Billotti GM.** Estimating the return-on-investment from changes in employee health risks on the Dow Chemical Company’s health care costs. *Journal of Occupational and Environmental Medicine* 2005; 47(8): 759–768.



- Goetzel RZ, Ozminkowski RJ, Bowen J, Tabrizi MJ,** Weiss A, Hohlbauch A, DeJoy DM, Wilson M, Roemer EC, Mummert A, **Baker K, Short M,** Liss-Levinson R, Samoly D. Employer integration of health promotion and health protection programs. *International Journal of Workplace Health Management* 2008; 1(2): 109–122.
- Goetzel RZ, Ozminkowski RJ,** Bruno JA, Rutter KR, Isaac F, **Wang S.** The long term impact of Johnson & Johnson's Health & Wellness program on employee health risks. *Journal of Occupational and Environmental Medicine* 2002; 44(5): 417–424.
- Goetzel RZ, Ozminkowski RJ, Long SR.** Development and reliability analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(7): 743–762.
- Goetzel RZ, Ozminkowski RJ,** Pelletier KR, Metz RD, Chapman LS. Emerging trends in health and productivity management. *American Journal of Health Promotion* 2007; 22(1): Suppl 1–7, iii.
- Goetzel RZ, Ozminkowski RJ, Schutt DC.** Pharmaceuticals—cost or investment? Chapter 36 in *Employee Benefit Issues: The Multiemployer Perspective*. Volume 43 (2001), Brookfield, WI: International Foundation of Employee Benefit Plans.
- Goetzel RZ, Ozminkowski RJ,** Sederer LI, **Mark TL.** The business case for quality mental health services: Why employers should care about the health and well-being of their employees. *Journal of Occupational and Environmental Medicine* 2002; 44(4): 320–330.
- Goetzel RZ, Ozminkowski RJ,** Sederer LI, **Mark TL.** Working with depression, part I: The case for quality mental health services. *Business and Health* 2002; August 1.
- Goetzel RZ, Ozminkowski RJ,** Sederer LI, **Mark TL.** Working with depression, part II: Finding and funding effective treatment. *Business and Health* 2002; August 1.
- Goetzel RZ, Ozminkowski RJ,** Villagra VG, Duffy J. Return on investment in disease management: A review. *Health Care Financing Review* 2005; 26(4): 1–19.
- Goetzel RZ, Ozminkowski RJ, Yuhasz L.** Health and productivity management: What does this have to do with health promotion? Adapted by Wolf Kirstein, *Health Promotion Global Perspectives* 2002; 4(2): 2–3.
- Goetzel RZ, Ozminkowski RJ.** Disease management as a part of total health and productivity management. *Disease Management & Health Outcomes* 2000; 8(3): 121–128.
- Goetzel RZ, Ozminkowski RJ.** Health and productivity management: Emerging opportunities for health promotion professionals for the 21st century. *American Journal of Health Promotion* 2000; 14(4): 211–214.
- Goetzel RZ, Ozminkowski RJ.** Program evaluation. Chapter 5, *Health Promotion in the Workplace*, Third Edition, Michael P. O'Donnell (ed.), Albany, NY: Delmar/Thomson Learning, 2002.
- Goetzel RZ,** Reynolds K, Breslow L, Roper WL, **Shechter D,** Stapleton DC, Lapin PJ, McGinnis JM. Health promotion in later life: It's never too late. *American Journal of Health Promotion* 2007; 21(4): 1–5, iii.



- Goetzel RZ**, Roemer EC, **Short ME**, **Pei X**, **Tabrizi MJ**, Liss-Levinson RC, Samoly DK, Luisi D, Quitoni K, Dumanovsky T, Silver LD, **Ozminkowski RJ**. Health improvement from a worksite health promotion private-public partnership. *Journal of Occupational and Environmental Medicine* 2009; 51(3): 296–304.
- Goetzel RZ**, **Shechter D**, **Ozminkowski RJ**, Marmet PF, **Tabrizi MJ**, Roemer EC. Promising practices in employer health and productivity management efforts: Findings from a benchmarking study. *Journal of Occupational and Environmental Medicine* 2007; 49(2): 111–130.
- Goetzel RZ**, **Shechter D**, **Ozminkowski RJ**, Stapleton DC, Lapin PJ, McGinnis JM, Gordon CR, Breslow L. Can health promotion programs save Medicare money? *Clinical Interventions in Aging* 2007; 2(1): 117–122.
- Goetzel RZ**. A corporate perspective: Reflections from the economic buyer of health promotion programs (introduction to the Corporate Perspectives section of special issue). *American Journal of Health Promotion* 2001; 15(5): 357.
- Goetzel RZ**. The financial impact of health promotion and disease prevention programs—Why is it so hard to prove value? (introduction to special issue). *American Journal of Health Promotion* 2001; 15(5): 277–80.
- Hawkins K**, **Wang S**, Rupnow MF. Indirect cost burden of migraine in the United States. *Journal of Occupational and Environmental Medicine* 2007; 49(4): 368–374.
- Johnston SS**, **Mark TL**, Dirani R. Smoking cessation: The value of a comprehensive carved-in benefit. *American Journal of Health Promotion* 2008; 23(2): 85–7, ii.
- Leutzinger JA, **Ozminkowski RJ**, Dunn RL, **Goetzel RZ**, Richling DE, Stewart M, Whitmer RW. Projecting future medical care costs using four scenarios of lifestyle risk rates. *American Journal of Health Promotion* 2000; 15(1): 35–44.
- Lynch WD, Chikamoto Y, Imai K, Lin TF, Kenkel DS, **Ozminkowski RJ**, **Goetzel RZ**. The association between health risks and medical expenditures in a Japanese corporation. *American Journal of Health Promotion* 2005; 19(3 Suppl.): 238–248.
- Matson Koffman DM, **Goetzel RZ**, Anwuri VV, Shore KK, Orenstein D, LaPier T. Heart healthy and stroke free: successful business strategies to prevent cardiovascular disease. *American Journal of Preventative Medicine* 2005; 29(5 Suppl 1): 113–21.
- Mitchell SG**, **Goetzel RZ**, **Ozminkowski RJ**. The value of worksite health promotion. *ACSM's Health & Fitness Journal* 2008; 12(2): 23–27.
- Naydeck BL, Pearson JA, **Ozminkowski RJ**, Day BT, **Goetzel RZ**. The impact of the Highmark employee wellness programs on 4-year healthcare costs. *Journal of Occupational and Environmental Medicine* 2008; 50(2): 146–156.
- Nicholson S, Pauly MV, Polsky D, Baase CM, Billotti GM, **Ozminkowski RJ**, Berger ML, Sharda CE. How to present the business case for healthcare quality to employers. *Applied Health Economics and Health Policy* 2005; 4(4): 209–218.



- Ozminkowski RJ, Goetzel RZ, Chang S, Long S.** The application of two health and productivity instruments at a large employer. *Journal of Occupational and Environmental Medicine* 2004; 46(7): 635–648.
- Ozminkowski RJ, Goetzel RZ, Crown WH.** Productivity measurement for pharmacoeconomic and outcomes research studies. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) News* 2001; December 15.
- Ozminkowski RJ, Goetzel RZ, Long SR.** A validity analysis of the work productivity short inventory (WPSI) instrument measuring employee health and productivity. *Journal of Occupational and Environmental Medicine* 2003; 45(11): 1183–1195.
- Ozminkowski RJ, Goetzel RZ, Santoro J, Saenz BJ, Eley C, Gorsky B.** Estimating risk reduction required to break even in a health promotion program. *American Journal of Health Promotion* 2004; 18(4): 316–325.
- Ozminkowski RJ, Goetzel RZ, Smith MW, Cantor RI, Shaughnessy A, Harrison M.** The impact of the Citibank, N.A., health management program on changes in employee health risks over time. *Journal of Occupational and Environmental Medicine* 2000; 42(5): 502–511.
- Ozminkowski RJ, Goetzel RZ.** Getting closer to the truth: Overcoming research challenges when estimating the financial impact of worksite health promotion programs. *American Journal of Health Promotion* 2001; 15(5): 289–295.
- Ozminkowski RJ, Goetzel RZ, Wang F, Gibson TB, Shechter D, Musich S, Bender J, Edington DW.** The savings gained from participation in health promotion programs for Medicare beneficiaries. *Journal of Occupational and Environmental Medicine* 2006; 48(11): 1125–1132.
- Ozminkowski RJ, Ling D, Goetzel RZ, Bruno JA, Rutter KR, Isaac F, Wang S.** Long-term impact of Johnson & Johnson's Health & Wellness program on health care utilization and expenditures. *Journal of Occupational and Environmental Medicine* 2002; 44(1): 21–29.
- Ozminkowski RJ, Mark T, Cangianelli L, Walsh JM, Davidson R, Blank D, Flegel RR, Goetzel RZ.** The cost of on-site vs. off-site workplace urinalysis testing for illicit drug use. *Health Care Manager* 2001; 20(1): 59–69.
- Ozminkowski RJ, Mark TL, Goetzel RZ, Blank D, Walsh JM, Cangianelli L.** Relationships between urinalysis testing for substance use, medical expenditures, and the occurrence of injuries at a large manufacturing firm. *The American Journal of Drug and Alcohol Abuse* 2003; 29(1): 151–167.
- Ozminkowski RJ, Wang S, Walsh JK.** The direct and indirect costs of untreated insomnia in the United States. *Sleep* 2007; 30(3): 263–73.
- Pratt CA, Lemon SC, Fernandez ID, **Goetzel R**, Beresford SA, French SA, Stevens VJ, Vogt TM, Webber LS. Design characteristics of worksite environmental interventions for obesity prevention. *Obesity* 2007; 15(9): 2171–80.
- Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, Dejoy DM, Wilson MG.** How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. *Journal of Occupational and Environmental Medication* 2009; 51(7): 786–96.



Song X, Huse DM, Williams SA, Borok GM, McDonough K, Ozminkowski RJ. A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. *Journal of Occupational and Environmental Medicine* 2006; 48(10): 1014–22.

Turpin RS, **Ozminkowski RJ**, Sharda CE, Collins JJ, Berger ML, Billotti GM, Baase CM, Olson MJ, Nicholson S. Reliability and validity of the Stanford Presenteeism Scale. *Journal of Occupational and Environmental Medicine* 2004; 46(11): 1123–1133.

Wilson MG, **Goetzel RZ, Ozminkowski RJ**, DeJoy DM, Della L, Roemer EC, Schneider J, Tully KJ, White JM, Baase CM. Using formative research to develop environmental and ecological interventions to address overweight and obesity. *Obesity* 2007; 15(Suppl 1): 37S–47S.

Long-Term Care

Burwell B. Medicaid long-term care expenditures in fiscal year 2000. *Gerontologist* 2001; 41(5): 687–691.

Shea D, **Russo P**, Smyer M. Use of mental health services by persons with a mental illness in nursing facilities: Initial impacts of OBRA87. *Journal of Aging and Health* 2000; 12(4): 560–577.

Men's Health

Thomas P, **Goetzel RZ, Ozminkowski RJ**, Kassabian VS, **Schutt DC.** If men won't go to doctors... *Business and Health* 2002; June 19.

Thomas P, **Goetzel RZ, Ozminkowski RJ**, Kassabian VS, **Schutt DC.** Results of a men's urological health screening program at Lockheed Martin Aeronautical Systems. *Disease Management Health Outcomes* 2003; 11(3): 181–189.

Depression

Alegría M, Chatterji P, Wells K, **Cao Z**, Chen CN, Takeuchi D, Jackson J, Meng XL. Disparity in depression treatment among racial and ethnic minority populations in the United States. *Psychiatric Services* 2008; 59(11): 1264–72.

Crown W, Finkelstein S, Berndt E, **Ling D, Poret A**, Rush J, Russell J. The impact of treatment-resistant depression on healthcare utilization and costs. *Journal of Clinical Psychiatry* 2002; 63(11): 963–971.

Crown W, Treglia M, **Meneades L, White A.** Long-term costs of treatment for depression: Impact of drug selection and guideline adherence. *Value in Health* 2001; 4(4): 295–307.



- Crown W**, Wan G, Berndt E, Finkelstein S, **Ling D**. Differences in health care expenditures among patients treated for depression with or without anxiety. *Value in Health* 2001; 4(2): 148.
- Crown W**. Antidepressant selection and economic outcome: A review of methods and studies from clinical practice. *British Journal of Psychiatry* 2001; 179 (42 Suppl.): s18–s22.
- Crown W**. Antidepressant use and clinical and economic outcomes in a primary care psychiatry center in Spain: A review of a naturalistic study. J. Guimón and N. Sartorius (eds) *Manage or Perish?* Kluwer Academic Publishers, 2000.
- Crown W**. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression. *Acta Psychiatrica Scandinavica* 2000; 101 (403 Suppl.): 62–66.
- Henke RM**, Chou AF, Chanin JC, Zides AB, Scholle SH. Physician attitude toward depression care interventions: Implications for implementation of quality improvement initiatives. *Implementation Science* 2008; 3: 40.
- Henke RM**, Zaslavsky AM, McGuire TG, Ayanian JZ, Rubenstein LV. Clinical inertia in depression treatment. *Medical Care* 2009; 47(9): 959–67.
- Larson MJ, **Miller K**, Fleming KJ. Antidepressant medication use in private insurance health plans, 2002. *Psychiatric Services* 2006; 57(2): 175.
- Larson MJ, **Miller K**, Fleming KJ. Treatment with antidepressant medications in private health plans. *Administration and Policy in Mental Health* 2007; 34(2): 116–26.
- Mark TL**. Receipt of psychotherapy by adolescents taking antidepressants. *Psychiatric Services* 2008; 59(9): 963.
- Poret AW**, Neslusan C, Ricci JF, **Wang S**, Khan ZM, Kwong JW. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. *Value Health* 2001; 4(5): 362–369.
- Robinson RL, **Long SR**, **Chang S**, Able S, **Baser O**, Obenchain RL, Swindle RW. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *Journal of Managed Care Pharmacy* 2006; 12(1): 43–54.
- Russell J, **Hawkins K**, **Ozminkowski R**, **Orsini L**, **Crown W**, **Kennedy S**, Finkelstein S, Berndt E, Rush J. Cost consequences of treatment-resistant depression. *Journal of Clinical Psychiatry* 2004; 65(3): 341–347.

Schizophrenia

- Barrio C, Yamada AM, Atuel H, Hough RL, Yee S, Berthot B, **Russo PA**. A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders. *Schizophrenia Research* 2003; 60(2–3): 259–69.



- Citrome L, Reist C, **Palmer L, Montejano L, Lenhart G**, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. *Schizophrenia Research* 2009; 108(1–3): 238–44.
- Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R**, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. *Administration and Policy in Mental Health* 2001; 28(5): 335–351.
- Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, **Russo PA, Crown WH**. The schizophrenia care and assessment program health questionnaire (SCAP_HA): An instrument to assess outcomes of schizophrenia care. *Schizophrenia Bulletin* 2003; 29(2): 247–256.
- Mark TL, Palmer LA, Russo PA**, Vasey J. Examination of treatment pattern differences by race. *Mental Health Services Research* 2003; 5(4): 241–250.
- Mark TL**. Preferences among antipsychotic medications given particular clinical scenarios. *Schizophrenia Research* 2004; 66(1): 71–73.
- Mark, TL, Dirani R**, Slade E, **Russo PA**. Access to new medications to treat schizophrenia. *Journal of Behavioral Health Services Research* 2002; 29(1): 15–29.
- Russo PA, Smith MW**, Namjoshi M. Health care costs for schizophrenia patients started on olanzapine versus risperidone. *American Journal of Health-System Pharmacy* 2005; 62(6): 610–615.
- Salkever DS, Slade EP, Karakus M, **Palmer L, Russo PA**. Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. *The Journal of Nervous and Mental Disease* 2004; 192(2): 119–128.
- Slade EP, Salkever DS, Rosenheck R, Swanson J, Swartz M, Shern D, Gallucci G, Harding C, **Palmer L, Russo P**, Hough RL, Barrio C, Garcia P. Cost-sharing requirements and access to mental health care among medicare enrollees with schizophrenia. *Psychiatric Services* 2005; 56(8): 960–6.

Substance Abuse

- Bray J, Vandivort R, Dilonardo J, Dunlap L, **Schroeder D, Forhan C, Miller K**. Healthcare utilization of individuals with opiate use disorders: An analysis of integrated Medicaid and state mental health/substance abuse agency data. *Journal of Behavioral Health Services & Research* 2008; 35(1): 91–106.
- Coffey RM, Levit KR, Kassed CA**, McLellan AT, Chalk M, Brady TM, Vandivort-Warren R. Evidence for substance abuse services and policy research: A systematic review of national databases. *Evaluation Review* 2009; 33(2): 103–37.
- Dilonardo J, Chalk M, **Mark TL, Coffey RM**, CSAT/CMHS Spending Estimates Team. Recent trends in the financing of substance abuse treatment: Implications for the future. *Health Services Research* 2000; 35(5 Pt 3): 60–71.
- Fowler JS, Volkow ND, **Kassed CA**, Chang L. Imaging the addicted human brain. *Science and Practice Perspectives* 2007; 3(2): 4–16.



- Gabel JR, Whitmore H, Pickreign JD, **Levit KR, Coffey RM**, Vandivort-Warren R. Substance abuse benefits: Still limited after all these years. *Health Affairs* 2007; 26(4): w474–82.
- Kranzler HR, Stephenson JJ, **Montejano L, Wang S**, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. *Addiction* 2008; 103(11): 1801–8.
- Mark TL, Coffey RM**, Vandivort-Warren R, Harwood HJ, King EC, MHSA Spending Estimates Team. U.S. spending for mental health and substance abuse treatment, 1991–2001. *Health Affairs* 2005; Jan–Jun Suppl Web Exclusives: W5–133–W5–142.
- Mark TL, Coffey RM**. What drove private health insurance spending on mental health and substance abuse care, 1992–1999? *Health Affairs* 2003; 22(1): 165–72.
- Mark TL**, Dilonardo JD, Chalk M, **Coffey R**. Factors associated with the receipt of treatment following detoxification. *Journal of Substance Abuse Treatment* 2003; 24(4): 299–304.
- Mark TL**, Dilonardo JD, Chalk M, **Coffey RM**. Trends in detoxification services: 1992–1997. *Journal of Substance Abuse Treatment* 2002; 23(4): 253–260.
- Mark TL, Kassed CA**, Vandivort-Warren R, **Levit KR**, Kranzler HR. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. *Drug and Alcohol Dependence* 2009; 99(1-3): 345–9.
- Mark TL**, Kranzler HR, Poole VH, Hagen CA, McLeod C, Crosse S. Barriers to the use of medications to treat alcoholism. *American Journal on Addictions* 2003; 12(4): 281–294.
- Mark TL**, Kranzler HR, **Song X**, Bransberger P, Poole VH, Crosse S. Physicians' opinions about medications to treat alcoholism. *Addiction* 2003; 98(5): 617–626.
- Mark TL**, Kranzler HR, **Song X**. Understanding US addiction physicians' low rate of naltrexone prescription. *Drug and Alcohol Dependence* 2003; 71(3): 219–228.
- Mark TL, Levit KR**, Vandivort-Warren R, **Coffey RM**, Buck JA, the SAMHSA Spending Estimates Team. Trends in spending for substance abuse treatment, 1986–2003. *Health Affairs* 2007; 26(4): 1118–28.
- Mark TL, Song X**, Vandivort R, Duffy S, Butler J, **Coffey R**, Schabert V. Characterizing substance abuse programs that treat adolescents. *Journal of Substance Abuse Treatment* 2006; 31(1): 59–65.
- Mark TL**, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. *Health Economics* 2004; 13(6): 563–573.
- Mark TL**, Swait J. Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. *Value in Health* 2003; 6(4): 474–482.
- Mark TL**, Vandivort-Warren R, **Montejano L**. Factors affecting detoxification readmission: Analysis of public sector data from three states. *Journal of Substance Abuse Treatment*. 2006; 31(4): 439–45.
- Mark TL**, Woody GE, **Juday T**, Kleber HD. The economic costs of heroin addiction in the United States. *Drug and Alcohol Dependence* 2001; 61(2): 195–206.



- Mark TL.** Are medications for alcoholism underutilized? An analysis of private sector and Medicaid claims. *Drug Benefit Trends* 2004; 16(3): 154–158.
- Mark TL.** The costs of treating persons with depression and alcoholism compared with depression alone. *Psychiatric Services* 2003; 54(8): 1095–1097.
- Mark, TL, Coffey RM.** The decline in receipt of substance abuse treatment by the privately insured, 1992–2001. *Health Affairs* 2004; 23(6): 157–162.
- Russell M, **Chu BC**, Banerjee A, Fan AZ, Trevisan M, Dorn JM, Gruenewald P. Drinking patterns and myocardial infarction: A linear dose-response model. *Alcoholism, Clinical and Experimental Research* 2009; 33(2): 324–31.

Other Mental Health

.....

- Bray JW, Davis KL, Graver L, **Schroeder D**, Buck JA, Dilonardo J, Vandivort R. Mental health and substance abuse treatment utilization among individuals served by multiple public agencies in 3 states. *Journal of Behavioral Health Services & Research* 2005; 32(3): 282–93.
- Buck JA, **Mark TL.** Datapoints: State-administered spending on mental health services by type of service. *Psychiatric Services* 2006; 57(1): 29.
- Coffey RM**, Buck JA, **Kassed CA**, Dilonardo J, **Forhan C**, **Marder WD**, Vandivort-Warren R. Transforming mental health and substance abuse data systems in the United States. *Psychiatric Services* 2008; 59(11): 1257–63.
- Crystal-Peters J**, **Chang S**, **Long S**, Tretiak R. Health care expenditures of patients with major depressive disorder and post traumatic stress disorder. *European Psychiatry* 2002; 17 (1 Suppl.): 150.
- Dilonardo J, **Coffey R**, Vandivort-Warren R, Buck J. Inpatient utilization for persons with co-occurring disorders. *Psychiatric Services* 2008; 59(1): 14.
- Ettner SL, Frank RG, **Mark TL**, **Smith MW.** Risk adjustment of capitation payments to behavioral health care carve-outs: How well do existing methodologies account for psychiatric disability? *Health Care Management Science* 2000; 3(2): 159–169.
- Finkel S, Kozma C, **Long S**, Greenspan A, Mahmoud R, **Baser O**, Engelhart L. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. *International Psychogeriatrics* 2005; 17(4): 1–13.
- Finkelstein E, Bray J, Larson MJ, **Miller K**, Tompkins C, Keme A, Manderscheid R. Prevalence of, and payments for, mental health and substance abuse disorders in public and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States 2002, 165–185, 2004.
- Harwood HJ, **Mark TL**, McKusick DR, **Coffey RM**, King EC, Genuardi JS. National spending on mental health and substance abuse treatment by age of clients, 1997. *The Journal of Behavioral Health Services & Research* 2003; 30(4): 433–43.



- Larson MJ, **Miller K**, Fleming KJ, Teich JL. Mental health services for children in large, employer-based health plans, 1999. *The Journal of Behavioral Health Services & Research* 2007; 34(1): 56–72.
- Levit KR, Kassed CA, Coffey RM, Mark TL**, Stranges EM, Buck JA, Vandivort-Warren R. Future funding for mental health and substance abuse: Increasing burdens for the public sector. *Health Affairs* 2008; 27(6): w513–22.
- Ling D**, Bresnahan B, **White A**, Neslusan C, **Crown W**. Risk of hospitalization for patients with bipolar disorder. *Value in Health* 2001; 4(2): 144.
- Mark TL**, Buck J. Characteristics of U.S. youths with serious emotional disturbance: Data from the national health interview survey. *Psychiatric Services* 2006; 57(11): 1573–8.
- Mark TL**, Buck JA, Dilonardo JD, **Coffey RM**, Chalk M. Medicaid expenditures on behavioral health care. *Psychiatric Services* 2003; 54(2): 188–194.
- Mark TL**, Buck JA. Components of spending for Medicaid mental health services, 2001. *Psychiatric Services* 2005; 56(6): 648.
- Mark TL, Coffey RM**, King E, Harwood H, McKusick D, Genuarid J, Dilonardo J, Buck J. Spending on mental health and substance abuse treatment, 1987–1997. *Health Affairs* 2000; 19(4): 108–120.
- Mark TL, Coffey RM**, Vandivort-Warren R, Harwood HJ, King EC, MHSA Spending Estimates Team. U.S. spending for mental health and substance abuse treatment, 1991–2001. *Health Affairs* 2005; Jan–Jun Suppl Web Exclusives: W5–133–W5–142.
- Mark TL**, Harwood HJ, McKusick DC, King EC, Vandivort-Warren R, Buck JA. Mental health and substance abuse spending by age, 2003. *Journal of Behavioral Health Services and Research* 2008; 35(3): 279–89.
- Mark TL, Levit KR**, Buck JA. Datapoints: Psychotropic drug prescriptions by medical specialty. *Psychiatric Services* 2009; 60(9): 1167.
- Mark TL, Levit KR, Coffey RM**, Buck JA, Vandivort-Warren R. Mental health treatment expenditure trends, 1986–2003. *Psychiatric Services* 2007; 58(8):1041–8.
- Mark TL, Palmer LA, Russo PA**, Vasey J. Examination of treatment pattern differences by race. *Mental Health Services Research* 2003; 5(4): 241–250.
- McCulloch JM, **Ozminkowski RJ**, Cuffel B, Dunn RL, Goldman W, Kelleher D, **Comporato A**. Analysis of a managed psychiatric disability program. *Journal of Occupational and Environmental Medicine* 2001; 43(2): 101–109.
- McKusick DR, **Mark TL**, King EC, **Coffey RM**, Genuardi J. Trends in mental health insurance benefits and out-of-pocket spending. *The Journal of Mental Health Policy and Economics* 2002; 5(2): 21–31.
- Montejano LB, Goetzel RZ, Ozminkowski RJ**. Impact of bipolar disorder on employers: Rationale for workplace interventions. *Disease Management and Health Outcomes* 2005; 13(4): 267–280.
- Mucha L**, Shaohung S, Cuffel B, McRae T, **Mark TL**, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. *Journal of Managed Care Pharmacy* 2008; 14(5): 451–61.



- Rothbard AB, **Miller K**, Lee S, Blank M. Revised cost estimates of Medicaid recipients with serious mental illness and HIV-AIDS. *Psychiatric Services* 2009; 60(7): 974–7.
- Russo P, Smith MW, Dirani R**, Namjoshi M, Tohen M. Pharmacotherapy patterns in the treatment of bipolar disorder. *Bipolar Disorder* 2002; 4(6): 366–377.
- Teich J, **Buck J, Graver L, Schroeder D, Zheng D**. Utilization of public mental health services by children with serious emotional disturbances. *Administration and Policy in Mental Health* 2003; 30(6): 523–34.
- Thomas CP, Hodgkin D, Wallack SS, Martin T, Ritter GA, **Mark TL**. Mental health and substance abuse treatment prescription drugs: Lessons from a period of high spending growth. *Journal of Pharmaceutical Finance, Economics & Policy* 2007; 16(3): 67–83.
- Wan GJ, **Crown WH**, Berndt ER, Finkelstein SN, **Ling D**. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. *International Journal of Clinical Practice* 2002; 56(6): 434–439.

Oncology

.....

- Berndt E, **Crown W**. Labor force activity in cancer patients with anemia. *Quality of Life in Oncology* 2002; 5(4): 10–13.
- Bradley CJ, Given C, **Baser O**, Gardiner J. Influence of surgical and treatment choices on the cost of breast cancer care. *European Journal of Health Economics* 2003; 4: 96–101.
- Chang S, Long SR**, Kutikova L, Bowman L, **Crown WH**, Lyman GH. Burden of pancreatic cancer and disease progression: Economic analysis in the US. *Oncology* 2006; 70(1): 71–80.
- Chang S, Long SR**, Kutikova L, Bowman L, Finley D, **Crown WH**, Bennett CL. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. *Journal of Clinical Oncology* 2004; 22(17): 3524–3530.
- Chu E, **Schulman KL**, Zelt S, **Song X**. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. *Cancer* 2009; 115(7): 1412–23.
- Chu E, **Shi N**, Wei W, Bendell JC, Cartwright T. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. *Oncology* 2009; 77(3–4): 244–53.
- Duh MS, **Mark TL**. Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy related anemia. *Expert Review of Pharmacoeconomics and Outcomes Research* 2005; 5(4): 383–394.
- Gosselein A, Pasho CL, Harley C, **Mark TL**, McKenzie RS. Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies. *Clinical Therapeutics* 2006; 28(10): 1701–09.



- Joseph AK, **Mark TL**, Mueller C. The period prevalence and costs of treating nonmelanoma skin cancers in patients over 65 years of age covered by medicare. *Dermatologic Surgery* 2001; 27(11): 955–9.
- Krupski TL, **Foley KA**, **Baser O**, **Long S**, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy, and bone complications. *The Journal of Urology* 2007; 178(4 Pt 1): 1423–8.
- Kutikova L, Bowman L, **Chang S**, **Long SR**, Arning M, **Crown WH**. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. *Leukemia & Lymphoma* 2006; 47(8): 1535–44.
- Kutikova L, Bowman L, **Chang S**, **Long SR**, Thornton DE, **Crown WH**. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. *Journal of Neurooncology* 2007; 81(1): 61–5.
- Kutikova L, Bowman L, **Chang S**, **Long SR**, Obasaju C, **Crown WH**. The economic burden of lung cancer and the associated costs of treatment failure in the United States. *Lung Cancer* 2005; 50(2): 143–154.
- Lee DW, Stang PE, Goldberg GA, **Haberman M**. Resource use and cost of diagnostic workup of women with suspected breast cancer. *The Breast Journal* 2009; 15(1): 85–92.
- Lyman GH, Berndt ER, Kallich JD, Erder MH, **Crown WH**, **Long SR**, Lee H, **Song X**, Finkelstein SN. The economic burden of anemia in cancer patients receiving chemotherapy. *Value in Health* 2005; 8(2): 149–156.
- Madeb R, Golijanin D, Noyes K, Fisher S, **Stephenson JJ**, **Long SR**, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: Do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. *Cancer* 2009; 115(12): 2660–70.
- Mark TL**, Fortner B, Johnson G. Evaluation of a tablet PC technology to screen and educate oncology patients. *Supportive Care in Cancer* 2008; 16(4): 371–8.
- Mark TL**, Johnson G, Fortner B, **Ryan K**. The benefits and challenges of using computer-assisted symptom assessments in oncology clinics: Results of a qualitative assessment. *Technology in Cancer Research & Treatment* 2008; 7(5): 401–6.
- Mark TL**, McKenzie RS, Fastenau J, Piech CT. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. *Current Medical Research and Opinion* 2005; 21(9): 1347–1354.
- Mortimer JE, **Schulman K**, Kohles JD. Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. *Clinical Breast Cancer* 2007; 7(9): 682–9.
- Papatheofanis F, Fahrback K, **Mark TL**, Chiang T, Frame D, Suruki RY, Scheye R, Drielick M, Nalysnyk L. A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents. *Journal of Clinical Oncology* 2004; 22(14S): 6114.
- Schulman KL**, Kohles J. Economic burden of metastatic bone disease in the U.S. *Cancer* 2007; 109(11): 2334–42.



Wynn ML, **Chang S**, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. *Journal of Women's Health* 2007; 16(7): 971–86.

Women's Health

Carls GS, Lee DW, **Ozminkowski RJ**, **Wang S**, **Gibson TB**, Stewart E. What are the total costs of surgical treatment for uterine fibroids? *Journal of Women's Health* 2008; 17(7): 1119–32.

Chawla A, Swindle R, **Long S**, **Kennedy S**, Sternfeld B. Premenstrual dysphoric disorder: Is there an economic burden of illness? *Medical Care* 2002; 40(11): 1101–1112.

Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. *BMC Women's Health* 2008; 8(1): 24.

Lee DW, **Gibson TB**, **Carls GS**, **Ozminkowski RJ**, **Wang S**, Stewart EA. Uterine fibroid treatment patterns in a population of insured women. *Fertility and Sterility* 2009; 91(2): 566–74.

Lee DW, **Ozminkowski RJ**, **Carls GS**, **Wang S**, **Gibson TB**, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. *Journal of Occupational and Environmental Medicine* 2007; 49(5): 493–506.

Sternfeld B, Swindle R, **Chawla A**, **Long S**, **Kennedy S**. Severity of premenstrual symptoms in a health maintenance organization population. *Obstetrics & Gynecology* 2002; 99(6): 1014–1024.

Other

Baker LC, Phibbs CS, Guarino C, **Supina D**. Within-year variation in hospital utilization and its implications for hospital costs. *Journal of Health Economics* 2004; 23: 191–211.

Barr C, **Schulman K**, Iacuzio D, Bradley J. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. *Current Medical Research and Opinion* 2007; 23(3): 523–31.

Baser O. Choosing propensity score matching over regression adjustment for causal inference: When, why and how it makes sense. *Journal of Medical Economics* 2007; 10(4): 379–391.

Baser O. Modeling transformed health care cost with unknown heteroskedasticity. *Applied Economic Research* 2007; 01: 1–6.

Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. *Value in Health* 2006; 9(6): 377–85.



- Baser O.** Using propensity score matching techniques for average treatment effect: Application to triptan use. In *Proceedings of the International Conference on Health Policy Research*, October 28-30 2005, Boston, MA. American Statistical Association; 2007: 4334–4339.
- Baser O**, Bradley C, Gardiner J, Given B. Estimation from censored medical cost. *Biometrical Journal* 2004; 46: 351–363.
- Baser O**, Bradley C, Gardiner J, Given B. Testing and correcting non-random selection bias due to censoring: An application to medical costs. *Health Services and Outcomes Research Methodology* 2003; 4(2): 93–107.
- Baser O**, **Crown WH**, Pollicino C. Guidelines for selecting among different types of bootstraps. *Current Medical Research and Opinion* 2006; 22(4): 799–808.
- Baser O**, Gardiner J, Bradley C, Yuce H, Given B. Longitudinal analysis of censored medical cost. *Health Economics* 2006; 15(5): 513–525.
- Baser O**, **Palmer L**, **Stephenson J**. The estimation power of alternative comorbidity indices. *Value in Health* 2008; May 16; [Epub ahead of print].
- Blumentals WA, **Schulman KL**. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: Results from a retrospective population-based study. *Current Medical Research and Opinion* 2007; 23(12):2961–70.
- Blumentals WA, **Song X**. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. *Medscape General Medicine* 2007; 9(4): 27–32.
- Brooks J, Clark MA, **Crown B**, Davey P, Hutchins D, Martin B, Motheral B, Stang P. A checklist for retrospective database studies—Report of the ISPOR Task Force on Retrospective Databases. *Value in Health* 2003; (6)2: 90–97.
- Chernew M, **Gibson TB**. Cost sharing and HEDIS performance. *Medical Care Research and Review* 2008; 65(6): 713–28.
- Chernew M, **Gibson TB**, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. *Journal of General Internal Medicine* 2008; 23(8): 1131–6.
- Chu BC**, Millis S, Arango-Lasprilla JC, Hanks R, Novack T, Hart T. Measuring recovery in new learning and memory following traumatic brain injury: A mixed-effects modeling approach. *Journal of Clinical and Experimental Neuropsychology* 2007; 29(6): 617–25.
- Coben JH, Steiner CA, **Barrett M**, Merrill CT, Adamson D. Completeness of cause of injury coding in healthcare administrative databases in the United States, 2001. *Injury Prevention* 2006; 12(3): 199–201.
- Coffey RM**, Andrews RM, Moy E. Racial, ethnic, and socioeconomic disparities in estimates of AHRQ patient safety indicators. *Medical Care* 2005; 43(3 Suppl.): I48–57.
- Crown WH**, Bresnahan BW, **Orsini LS**, **Kennedy S**, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. *Current Medical Research and Opinion* 2004; 20(12): 1929–1936.



- Curkendall SM**, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois, RW. Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter? *Arthritis and Rheumatism* 2008; 59(10): 1519-26
- Curkendall SM**, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. *HIV Medicine* 2007; 8(8): 483-90.
- Dworkin RH, White R, O'Connor AB, **Baser O**, **Hawkins K**. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. *Journal of the American Geriatrics Society* 2007; 55(8): 1168-75.
- Dworkin RH, White R, O'Connor AB, **Hawkins K**. Health care expenditure burden of persisting herpes zoster pain. *Pain Medicine* 2008; 9(3): 348-53.
- Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, **Young JK**, Cooper LM. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: A database cohort study of hospital mortality, length of stay, and costs. *Current Medical Research and Opinion* 2007; 23(1): 235-44.
- Foley KA**, Foster SA, Meadows ES, **Baser O**, **Long SR**. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Medical Care* 2007; 45(9): 902-6.
- Foster SA, **Foley KA**, Meadows ES, Johnston JA, **Wang S**, Pohl GM, **Long SR**. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. *Osteoporosis International* 2008; 19(3): 373-7.
- Gibson TB**, Lee TA, Vogeli CS, Hidalgo J, **Carls GS**, **Sredl K**, DesHarnais S, **Marder WD**, Weiss KB, Williams TV, Shields AE. A four-system comparison of patients with chronic illness: The Military Health System, Veterans Health Administration, Medicaid, and commercial plans. *Military Medicine* 2009; 174(9): 936-43.
- Gibson TB**, Ng E, **Ozminkowski RJ**, **Wang S**, Burton WN, **Goetzel RZ**, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. *Journal of Occupational and Environmental Medicine* 2008; 50(11): 1261-1272.
- Glazer J, McGuire TG, **Cao Z**, Zaslavsky A. Using global rating of health plans to improve the quality of health care. *Journal of Health Economics* 2008; 27(5): 1182-95.
- Guo JJ, **Curkendall SM**, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. *Pharmacoepidemiology and Drug Safety* 2003; 12(4): 295-301.
- Hansen LG**. Is the glass half full or half empty? Patient dynamics underlying marketshare. *Product Management Today* 2004; 15(10): 37-39.
- Hawkins K**, **Wang S**, Rupnow M. Direct cost burden among insured US employees with migraine. *Headache* 2008; 48(4): 553-63.
- Hochberg MC, **Johnston SS**, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Current Medical Research and Opinion* 2008; 24(2): 469-80.



- Houchens RL**, Elixhauser A, Romano P. How often are potential “patient safety events” present on admission? *Joint Commission Journal on Quality and Patient Safety* 2008; 34(3): 154–163.
- Huse DM**, Castelli-Haley J, **Orsini LS**, **Lenhart G**, Abdalla JA, Patterns of initial pharmacotherapy for Parkinson’s disease in the United States. *Journal of Geriatric Psychiatry and Neurology* 2006; 19(2): 91–97.
- Huse DM**, **Schulman K**, **Orsini L**, Castelli-Haley J, **Kennedy S**, **Lenhart G**. Burden of illness in Parkinson’s disease. *Movement Disorders* 2005; 20(11): 1449–1454.
- Hutchings A, Calloway M, Choy E, Hooper M, Hunter DJ, Jordan JM, Zhang Y, **Baser O**, **Long S**, **Palmer L**. The Longitudinal Examination of Arthritis Pain (LEAP) study: relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. *The Journal of Rheumatology* 2007; 34(11): 2291–300.
- Jones JK, Fife D, **Curkendall SM**, Goehring E, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. *JAMA* 2001; 286(13): 1607–9.
- Kinchen KS, **Long S**, **Chang S**, Girts TK, Pantos B. The direct cost of stress urinary incontinence among women in a Medicaid population. *American Journal of Obstetrics & Gynecology* 2005; 193(6): 1936–1944.
- Kinchen KS, **Long S**, **Orsini L**, **Crown W**, Swindle R. A retrospective claims analysis of the direct costs of stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2003; 14(6): 403–411.
- Kinchen KS, **Orsini L**, **Crown W**, Bump R. Healthcare utilization among women who undergo surgery for stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2004; 15(3): 154–159.
- Kohli M, Attard C, Lam A, **Huse D**, Cook J, Bourgault C, Alemao E, Yin D, Marentette M. Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. *Pharmacoeconomics* 2006; 24: 815–830.
- Lee TA, Shields AE, Vogeli C, **Gibson TB**, Woong-Sohn M, **Marder WD**, Blumenthal D, Weiss KB. Mortality rate in veterans with multiple chronic conditions. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 403–7.
- Li T, **Carls GS**, Panopalis P, **Wang S**, **Gibson TB**, **Goetzel RZ**. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five-year analysis of a large Medicaid population. *Arthritis and Rheumatism* 2009; 61(6): 755–763.
- Madjid M, **Curkendall S**, Blumentals WA. The influence of oseltamivir treatment on the risk of stroke after influenza infection. *Cardiology* 2009; 113(2): 98–107.
- Mark HH, Robbins KP, **Mark TL**. Axial length in applanation tonometry. *Journal of Cataract and Refractive Surgery* 2002; 28(3): 504–6.
- Mark TL**, **Coffey RM**. Studying the effects of health plan competition: Are available data resources up to the task? *Health Services Research* 2001; 36(1 Pt 2): 253–275.



- Mark TL, Ozminkowski RJ, Kirk A, Ettner SL, Drabek J.** Risk adjustment for people with chronic conditions in private sector health plans. *Medical Decision Making* 2003; 23(5): 397–405.
- Mucha L, Stephenson J, Morandi N, Dirani R.** Meta-analysis of disease risk associated with smoking, by gender and intensity of smoking. *Gender Medicine* 2006; 3(4): 279–91.
- Orsini L, Rousculp MD, Long SR, Wang S.** Health care utilization and expenditures in the United States: A study of osteoporosis-related fractures. *Osteoporosis International* 2005; 16: 359–371.
- Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S.** The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. *Journal of Occupational & Environmental Medicine* 2006; 48(2): 135–148.
- Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, Sinskey AJ, Wierz D.** The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. *Clinical Therapeutics* 2004; 26(8): 1341–1354.
- Ozminkowski, RJ, Goetzel RZ, Shechter D, Stapleton DC, Baser O, Lapin P.** Predictors of preventive service use among Medicare beneficiaries. *Health Care Financing Review* 2006; 27(3): 5–23.
- Peters PH, Moscona A, **Schulman KL, Barr CE.** Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. *Medscape Journal of Medicine* 2008; 10(6): 131.
- Piedra PA, **Schulman KL, Blumentals WA.** Effects of oseltamivir on influenza-related complications in children with chronic medical conditions. *Pediatrics* 2009; 124(1): 170–8.
- Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J.** Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. *Disease Management* 2002; 5(2): 95–107.
- Romanowicz M, Stephenson JJ, Del Rosso JQ, **Lenhart G.** Healthcare utilization and costs of patients with rosacea in an insured population. *Journal of Drugs in Dermatology* 2008; 7(1): 41–9.
- Rousculp MD, **Long SR, Wang S, Schoenfeld MJ, Meadows ES.** Economic burden of osteoporosis-related fractures in Medicaid. *Value in Health* 2007; 10(2): 144–52.
- Safavi K.** Unintended consequences: Getting the most while avoiding the worst. *Journal of Healthcare Management* 2006; 51(6): 355–9.
- Saif MW, **Shi N, Zelt S.** Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. *World Journal of Gastroenterology* 2009; 15(35): 4415–22.
- Shi N, Foley K, Lenhart G, Badamgarav E.** Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. *Bone* 2009; August 5; [Epub ahead of print].
- Siddique R, **Neslusan CA, Crown WH, Crystal-Peters J, Sloan S, Farup C.** A national inpatient cost estimate of percutaneous endoscopic gastrostomy (PEG)-associated aspiration pneumonia. *The American Journal of Managed Care* 2000; 6(4): 490–496.
- Silverman S, Dukes EM, **Johnston SS, Brandenburg NA, Sadosky A, Huse DM.** The economic burden of fibromyalgia: Comparative analysis with rheumatoid arthritis. *Current Medical Research and Opinion* 2009; Feb 17; 25(4): 829–40.



- Song X, Long SR, Marder WD**, Sullivan SD, Kallich J. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. *Annals of Pharmacotherapy* 2009; 43(7): 1203–10.
- Stallings SC, **Huse D**, Finkelstein SN, **Crown WH**, Witt WP, Maguire J, Hiller AJ, Sinsky AJ, Ginsburg GS. A framework to evaluate the economic impact of pharmacogenomics. *Pharmacogenomics* 2006; 7(6): 853–62.
- Stang PE, **Crown WH, Bizier R**, Chatterton ML, White R. The family impact and costs of migraine. *The American Journal of Managed Care* 2004; 10(5): 313–320. (Kenneth M. Langa, MD, wrote an editorial about this article that was titled “An Illness in the Family: Accounting for the Complex Effects of Illness on Other Family Members” and was published in the same issue of *JOEM*.)
- Stull DE**, Rempher K, Jairath N, Kapustin J. The utility of multidimensional assessments of physical health in patient care. *AACN Clinical Issues* 2003; 14(2): 251–260.
- Sunyczec JA, **Mucha L, Baser O**, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. *Osteoporosis International* 2008; 19(10): 1421–9.
- Thomson Healthcare**. Bad debt, deductions, and utilization by payer. *Healthcare Financial Management* 2007; 61(8): 122–3.
- Unruh L, **Russo CA**, Jiang HJ, Stocks C. Can state-level data be used to develop a national, standardized dataset of hospital nurse staffing measures? *Western Journal of Nursing Research* 2009; 31(1): 66–88.
- Vogeli C, Shields AE, Lee TA, **Gibson TB, Marder WD**, Weiss KB, Blumenthal D. Multiple chronic conditions: Prevalence, health consequences and implications for quality, care management, and costs. *Journal of General Internal Medicine* 2007; 22 Suppl 3: 391–5.
- White RR, **Lenhart G**, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. *Pharmacoeconomics* 2009; 27(9): 781–92.
- Wish JB, Nassar GM, **Schulman K**, del Aguila M, Provenzano R. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. *Clinical Nephrology* 2008; 69(4): 251–9.
- Wish J, **Schulman K**, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: A retrospective claims database analysis. *Kidney and Blood Pressure Research* 2009; 32(2): 110–118.
- Yazici Y, **Shi N**, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: Analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. *Bulletin of the NYU Hospital for Joint Diseases* 2008; 66(2): 77–85.
- Zhan C, Elixhauser A, Friedman B, **Houchens R**, Chiang YP. Modifying DRG-PPS to include only diagnoses present on admission: Financial implications and challenges. *Medical Care* 2007; 45(4): 288–91.



THOMSON REUTERS

To contact Thomson Reuters regarding these and other authored studies, please call +1 866 301 5419 or e-mail medstat.marketscan@thomson.com.

(301)